PCD Pharma Franchise Opportunity with Edinburgh Pharmaceutical in Zirakpur, Chandigarh

-

 

The pharmaceutical industry is booming, and one of the most attractive business models emerging is the PCD Pharma franchise. If you’re looking for a reliable partner in the pharmaceutical sector, Edinburgh Pharmaceutical (A Division of Positive Medicare Pvt ltd.)  in Zirakpur, Chandigarh, offers a unique opportunity to grow your business with a trusted name in the market.

What is PCD Pharma?

PCD (Propaganda Cum Distribution) Pharma is a business model that allows entrepreneurs and small businesses to market pharmaceutical products under a reputable company’s brand. PCD Pharma companies provide exclusive marketing rights, promotional tools, and access to a wide range of high-quality medicines to their franchise partners, enabling them to grow their business with minimal risk.

pcd pharma franchise


Why Choose Edinburgh Pharmaceutical for PCD Pharma Franchise?

Located in Zirakpur, Chandigarh, Edinburgh Pharmaceutical is a well-established player in the pharmaceutical industry. With 15 years of experience and a reputation for delivering top-quality healthcare products, Edinburgh Pharma is a preferred choice for anyone seeking a PCD Pharma franchise. Here’s why:

1. Wide Range of Products:

Edinburgh Pharmaceutical offers a broad portfolio of pharmaceutical products, including:

  • Tablets
  • Capsules
  • Injections
  • Syrups
  • Ointments
  • Herbal and nutraceutical products

This different 600+ product range ensures that franchise partners can cater to various therapeutic areas such as cardiovascular, antibiotics, anti-inflammatory, ortho and more.

2. Monopoly Rights:

One of the key benefits of partnering with Edinburgh Pharmaceutical is the provision of monopoly rights. Franchisees are given exclusive rights to market the company’s products in their area, ensuring minimal competition and maximum market share.

3. High-Quality Standards:

Edinburgh Pharmaceutical adheres to strict quality control measures, ensuring that every product is manufactured in compliance with WHO-GMP standards. This not only guarantees the effectiveness of the medicines but also boosts trust among healthcare professionals and patients.

4. Comprehensive Support:

As a PCD Pharma franchise partner, you’ll receive extensive support from Edinburgh Pharmaceutical. The company provides a variety of promotional materials, such as:

  • Visual aids
  • Product samples
  • Marketing tools
  • MR (Medical Representative) kits

This support allows you to effectively promote the products in your region, increasing brand awareness and driving sales.

5. Affordable Investment:

Starting a PCD Pharma franchise with Edinburgh Pharmaceutical requires minimal investment. With low operational costs and the potential for high returns, this is an excellent opportunity for budding entrepreneurs or small businesses to enter the pharma industry.

How to Apply for a PCD Pharma Franchise with Edinburgh pharmaceutical?

If you are ready to become a part of the growing pharmaceutical industry with a trusted partner like Edinburgh Pharmaceutical, here’s how you can apply for a franchise:

  • Contact Edinburgh pharmaceutical via their website https://www.edinburghpharma.in/ 
  • Discuss the terms and conditions of the franchise agreement.
  • Choose your area of operation and sign the franchise deal.
  • Begin marketing high-quality products in your exclusive area!

Conclusion:

The PCD Pharma model is a game-changer for anyone looking to make a mark in the pharmaceutical industry. Edinburgh Pharmaceutical in Zirakpur, Chandigarh, offers an ideal opportunity for aspiring entrepreneurs to partner with a reputable pharma company and gain access to quality products, marketing rights, and monopoly benefits. With minimal investment and comprehensive support, this partnership can lead to significant growth in your business.

Take the first step toward building a successful future in the pharmaceutical industry by joining hands with Edinburgh Pharmaceutical today!



Get More Information Click On This Website Link - www.edinburghpharma.in and QR Code

#Anti-Diabetic PCD, #Best Pharma Companies, #Top Pcd Pharma Franchise in India, #Pcd Pharma Franchise Company, #Top PCD Pharma Franchise, #Top Pharma PCD, and #Top 10 Pharma Franchise , Best PCD Pharma Franchise Company, Pharma Franchise in Uttar Pradesh, Pharma Franchise in North East , PCD in West Bengal , Best Pharma Franchise















Location: India

Comments

Post a Comment

Popular posts from this blog

Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations. Leading Brands Available in India for Dapagliflozin + Sitagliptin + Metformin is SITPIN DM Promoted by Edinburgh Pharmaceuticals.

-
Image
Abstract Introduction:  This study compared efficacy and safety of triple drug fixed-dose combination (FDC) of dapagliflozin (DAPA) + sitagliptin (SITA) + metformin (MET) extended release (ER) with SITA + MET sustained release (SR) and DAPA + MET ER in patients with type 2 diabetes poorly controlled with metformin. Methods:  This phase 3, randomized, open-label, active-controlled study included adult patients with glycated hemoglobin (HbA1c) ≥ 8% (64 mmol/mol) and ≤ 11% (97 mmol/mol), randomized in 1:1:1 ratio to receive either FDC of DAPA + SITA + MET ER (10 mg + 100 mg + 1000 mg) tablets once daily (n = 137) or co-administration of SITA + MET SR (100 mg + 1000 mg) tablets once daily (n = 139) or FDC of DAPA + MET ER (10 mg + 1000 mg) tablets once daily (n = 139). Primary endpoint was mean change in HbA1c from baseline to week 16. Results:  Mean baseline HbA1c was approximately 9% (75 mmol/mol) in each treatment group. At week 16, adjusted mean reduction in HbA1c from ba...
Read more

Monteflo 3D ( Montelukast + Fexofenadine + Acebrophylline ) from Edinburgh Pharmaceutical

-
Image
Montelukast + Fexofenadine + Acebrophylline is a combination of three medicines: Montelukast, Fexofenadine and Acebrophylline. Montelukast is a leukotriene antagonist. It works by blocking the action of leukotriene, a chemical messenger.  This reduces inflammation in the airways and nose, and improves symptoms of allergies. Fexofenadine is an antiallergic which relieves symptoms like runny nose, watery eyes and sneezing. Acebrophylline is a mucolytic which thins and loosens mucus (phlegm), making it easier to cough out. Courte sy  Dr. Sakshi Sharma , Dr. Ashish Ranjan Get More Information Click On This Website Link  -  www.edinburghpharma.in   and  QR Code Click on Social Accounts - Facebook , LinkedIn & YouTube  Keywords :   #Pharma Franchise in Odisha #Anti-Diabetic PCD# Best PCD Pharma Franchise Company# High Quality Pharma Product# Third Party manufacturing # Top 10 Pharma Franchise# PCD in Uttar Pradesh# Monopoly Phama PCD# Best...
Read more

Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia. The leading brand of Tamiflo D range being promoted by Edinburgh Pharmaceuticals in India.

-
Image
  Abstract Background We performed a meta-analysis to confirm the efficacy and safety of the combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia (BPH) during a treatment cycle of at least 1 year. Methods Randomized controlled trials were searched by using MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. Systematic review was carried out using the Preferred Reporting Items for Systematic Reviews and Meta-analyses. The data was evaluated and statistically analyzed by using RevMan version 5.3.0. Results Five studies including 4348 patients were studied. The analysis found that the combination group was significantly greater effect in international prostate symptom score (mean difference [MD], − 1.43; 95% confidence interval [CI], − 2.20 to − 0.66;  P  = 0.0003), prostate volume (MD, − 10.13; 95% CI, − 12.38 to − 7.88;  P  < 0.00001), transitional zone volume (MD, − 3.18; 95% CI, − 3.57 to − ...
Read more